Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26
EQL Pharma AB (publ) will publish its interim report for the third quarter, 2025/26, on Tuesday, February 3[rd].
Media
Here you can take part in regulatory and non-regulatory press releases and presentations.
Read More
Press Releases
Notice of extraordinary general meeting in EQL Pharma AB
Regulatory
The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the extraordinary general meeting to be held on Tuesday 3 February 2026 at 13.00 at the company’s premises at Stortorg...
EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO)
Regulatory
As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for th...